COVID Vaccines Development/Procurement/Distribution/Policy – Russia, China

Milestones :: Perspectives :: Research


COVID Vaccines Development/Procurement/Distribution/Policy – Russia, China

Sputnik V – “the first registered COVID-19 vaccine” [to 26 Dec 2020]
Press Releases
First batch of 300,000 doses of Sputnik V vaccine delivered to Argentina
Press release, 24.12.2020

Argentina has registered the Sputnik V vaccine based on Russian clinical trial data
Press release, 23.12.2020
…Argentina was the first country in Latin America to officially register Sputnik V. The vaccine was registered under the emergency use authorization procedure and was approved by the regulator, ANMAT [National Administration of Drugs, Foods and Medical Devices of Argentina] based on the results of Phase III clinical trials in Russia, without additional trials in Argentina…

Production of Russian Sputnik V vaccine against coronavirus launched in Kazakhstan
Press release, 21.12.2020

Belarus becomes the first foreign country to register the Sputnik V vaccine
Press release, 21.12.2020




National Medical Products Administration [to 26 Dec 2020]
Official: Vaccines good for at least 6 months
The COVID-19 vaccine’s protection can last for more than half a year at least, said Zeng Yixin, deputy head of the National Health Commission, at news conference in Beijing on Dec 19.
He said the estimate is based on follow-up visits to No 3 People’s Hospital of Shenzhen, Guangdong province.
Six months after their recovery, 96 percent of people who had been infected with the novel coronavirus still had antibodies to protect them against new infections, the hospital said.
The follow-ups involved 506 people who had recovered from the infection between January and May.
The longest duration of for positive antibodies in this group was more than 10 months, the hospital said.
The purpose of the follow-up visits was to get an idea of how long the COVID-19 vaccines would provide protection, and to offer reference points in large-scale inoculation plans.
Zeng said there is no doubt that the protection the vaccines can provide is longer than half a year, as stipulated by the World Health Organization.
Even so, he said, it is still too early to say that the vaccines can realize lifetime protection, or provide five to 10 years’ protection.
Follow-up visits to the hospital will last for five years.

Official affirms safety of Chinese vaccines
Respecting laws of science fundamental principle in its development, he says
Experimental COVID-19 vaccines developed by Chinese researchers are safe, and ongoing efforts to push for their market approval will strictly follow the rules of science, a health official said on Dec 21.
China is conducting third-stage clinical trials for five Chinese-made vaccine candidates overseas and has administered emergency inoculations to nearly 1 million people in the country, according to Zheng Zhongwei, an official with the National Health Commission who is leading the task force on vaccine development.
“These vaccinations have fully demonstrated the safety of Chinese-made vaccines. There is some adverse reaction, but no severe adverse effect has been reported,” he said during a news conference on Monday.
He added that results from third-stage human trials are needed to determine the efficacy of these vaccines, although data from earlier phases of clinical trials and reports from recipients of emergency inoculations in high-risk countries have already shown the protective effects of these doses.
“Some leading developers have just obtained enough cases to conduct analysis of its efficacy. They have begun to submit materials needed for approval to the National Medical Products Administration,” Zheng said.
Market approval will only be granted after submitted trial findings meet the requirements of the top drug regulator, he added.
Zheng stressed that throughout the vaccine development process in China, respecting the laws of science has always been the fundamental principle…

China starts building COVID-19 vaccine production facility
China started the construction of a plant for manufacturing an mRNA-based COVID-19 vaccine on Dec 21, with production operations due to begin in eight months, according to local authorities.